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This year in particular saw the 
potential influenza pandemic fuel 
the uptake of immunisation against 
annual influenza. Judging from 
reports that both public and private 
sector vaccines ran out beforehand, 
the uptake must have been higher 
than usual, although no official 
reports are available to date. There 
were no significant reports of 
influenza illness in the community 
probably as a result of this. 
malformation increases if the illness 
develops in the first trimester, but the 
risk to the mother from the disease is 
greater in later pregnancy. Thus weighing 
the benefits and risks of treatment 
revolves mainly around these facts . 
These difficult situations could be 
easily avoided if individuals are 
immunised . The two dose vaccination 
schedule in adults provides about 75% 
protection. Being a Jive-attenuated virus 
vaccine, there is a potential risk of 
transmission to non-immune close 
contacts but this risk is very small. Non-
immune health care workers and women 
of child-bearing potential should be 
offered the vaccine. Immunosuppressed 
patients cannot have live virus vaccines, 
but their non-immune contacts can. A 
vaccine-associated rash may develop in 
10% of adults, and the vaccine virus 
strain may establish latent infection and 
reactivate as zoster at a later stage , but 
this is uncommon. 
Pneumococcal vaccine is probably 
under-prescribed . Besides being one of 
the most commonly reported cause of 
bacteraemia and meningitis, streptococcus 
pneumoniae frequently causes 
pneumonia and exacerbations of chronic 
obstructive pulmonary disease. Since 
2003, pneumococcal vaccine has been 
recommended for adults >65 years in 
the UK. Other immunocompetent adult 
groups who should receive it include 
those who are at increased risk of 
pneumococcal disease or its 
complications because of chronic 
illnesses like chronic respiratory disease, 
chronic heart disease, chronic liver 
disease, diabetes, individuals with 
cochlear implants and individuals with 
the potential for cerebrospinal fluid 
leaks. 
Tmmunosuppressed patients with 
asplenia or dysfunction of the sp leen , 
chronic renal disease, HIV, and long 
term use of steroids, should also be 
recommended for this vaccine, although 
the antibody response may be 
suboptimal. A good time to consider or 
plan immunisation would be during the 
ilnn! (ill fill vilrrination . The 
polysaccharide vaccine is effective in 
those >2 years old (in younger children, 
thp rnnjllfl<1tp vace-inp. i~ m.p.d). Re-
immunisation is not routinely offered 
but this is recommended in certain high 
risk groups like asplenic patients after 
five years. 
The hepatitis vaccines may be other 
examples of underutilised vaccines . 
The commonest indication for 
hepatitis A vaccine would be for 
contacts of an index case where the 
diagnosis is made within one week of 
the onset of symptoms. However this 
vaccine should also be considered in 
cases of chronic: livp.r disease (including 
hepatitis Band C infection), 
intravenous drug users, men who have 
sex with men , travellers to certain risk 
countries, persons with clotting 
disorders receiving regu lar blood 
products, and in potential occupational 
exposure as in healthcare or sewage 
workers. It is highly immunogenic and 
efficacious and booster doses after the 
primary two dose immunisation need 
not be given before 20 years . A 
combination vaccine with hepatitis B 
is available and sometimes, it would 
be more convenient when both need 
to be given. 
Since July 2002, hepatitis B vaccine is 
being offerred to all children in Malta 
during the fifth year. Older persons 
would have missed this and so need to 
be assessed for indications for the 
vaccine. Potential candidates include 
intravenous drug users and their close 
contacts, persons with multiple sexual 
partners, close family contacts of a 
hepatitis B carrier, individuals receiving 
regular blood or blood products, patients 
with chronic renal or liver disease , 
persons in certain institutions like 
prisons, travellers having high risk 
behaviour going to high risk areas, and 
individuals at occupational risk like 
health care workers. Pregnant hepatitis 
B positive females would need to 
immunise their babies at birth , along 
with hepatitis B immunoglobulin in 
some instances. In the case of accidental 
needle stick injury where the status of 
the blood on the needle is unknown, a 
risk assessment will need to be done 
prior to immunisation. 
Occasionally, situations arise where 
the routine immunisation status of an 
adult individual is unknown, and the 
individual comes forward to have these 
vaccines. The more important vaccines 
to be given would be three doses of 
tetanus, diphtheria and inactivated polio 
v~ccinp. with onCl month in h~twf'rn , 
with the fourth dose given one year later. 
Also , two doses of MMR are needed 
with three months in between 
immunisations. 
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Some would recommend 
meningococcal vaccine as well, especially 
in persons over 25 years of age and 
university attendees. BCG is not usually 
recommended to persons aged over 16 
years as the data for its effectiveness is 
not ilvilililhle However, it mily he 
recommended to high risk groups where 
risk of exposure is high. 
Travel related immunisations have 
increased in proportion with travel to 
areas at risk of specific infections. This 
is especially important in travel to Africa, 
South-East Asia and South America but 
not exclusive to these areas. Some 
travellers to forests in Northern Europe 
for example, may need cover for tick-
borne encephalitis. It is thus important 
to consult the latest travel advice 
according to the destination and planned 
activities in that country. 
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The challenges of the future include 
vaccines for HIV and hepati tis C. Up 
till now, these remain elusive , although 
graded successes are recorded in both 
fields. One of the latest HIV vaccines 
on trial showing promise uses a 
r1i~ilhlprl form of iln ;Jrlpnnvirm tn fprry 
three specific HIV genes into the body. 
Other organisms being targeted 
include malaria and leishmania, now 
that both their genomes have been 
sequenced . 
Some vaccines may protect against 
tumour development. The most well 
known is hepatitis B vaccine protecting 
against hepatoma. Other potential 
targets include papilloma virus, Ebstein-
Barr virus, and human T-cell 
lymphotropic virus I and H. Vaccines 
against diseases which are non-
communicable, like Alzheimer's disease, 
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have also shown some promising results 
in animal studies. D 
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